OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder's Meeting
NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.
The results of each resolution voted on can be found on the Company’s website in the “Investor – General Shareholders’ Meeting” section: https://ose-immuno.com/en/general-shareholders-meetings/.
In total, the shareholders who participated in person, by proxy to the chairman, by proxy to a third party or by postal vote, owned 8,149,700 shares representing 12,185,924 votes, i.e. 44.14% of the capital and 66% of the voting rights.
The shareholders approved the annual and consolidated financial statements as of December 31, 2021. They also approved the renewal of the term of office as director of Maryvonne Hiance, Didier Hoch and Nicolas Poirier (director representing the employee shareholders), which expired at this General Meeting, for three years. They also ratified the appointment of Alexandre Lebeaut as a new independent Director until the date of the present Shareholders’ Meeting and renewed his mandate as director for three years.
ABOUT OSE Immunotherapeutics
Immuno-Oncology first-in-class products
Immuno-Inflammation first-in-class products
CoVepiT: a prophylactic second-generation vaccine activating cytotoxic T lymphocytes against COVID-19, developed using optimized epitopes from SARS-CoV2 viral proteins, epitopes non impacted by multi-variants. Shows good tolerance and very good level of T cell immune response. In clinical testing, a long-term memory response was confirmed at 6 months.